Azeliragon (TTP488; PF-04494700)

Description: Azeliragon (also known as TTP488 and PF-04494700) is a potent and orally bioavailable RAGE (Receptor for Advanced Glycation End products) inhibitor that has the potential for the treatment of mild-to-moderate Alzheimer's disease and cerebral amyloid angiopathy. RAGE is a pattern recognition receptor that affects the movement of amyloid (a biomarker for Alzheimer's disease) into the brain. In preclinical studies, azeliragon decreased brain amyloid in mice and improved their performance on behavior tests. Azeliragon has been shown to be involved in adaptive immune responses. It is currently in Phase 3 clinical trial.

References: BMC Neurol. 2014 Jan 15; 14:12; Front Aging Neurosci. 2014 Oct 20; 6:290.

Related CAS#: 603148-36-3 (free base); 1284150-65-7 (2HCl)